Immunohistochemical expression and prognostic relevance of Bmi-1, a stem cell factor, in epithelial ovarian cancer

被引:53
作者
Abd El Hafez, Amal [1 ]
El-Hadaad, Hend Ahmed [2 ]
机构
[1] Mansoura Univ, Fac Med, Dept Pathol, Mansoura, Egypt
[2] Mansoura Univ, Fac Med, Clin Oncol & Nucl Med Dept, Mansoura, Egypt
关键词
Bmi-1; Epithelial ovarian cancer; Immunohistochemistry; Prognosis; Survival; POLYCOMB PROTEIN BMI-1; GROUP GENE BMI-1; TELOMERASE ACTIVITY; BREAST-CANCER; MOLECULAR MARKER; PROSTATE-CANCER; LUNG-CANCER; CARCINOMA; OVEREXPRESSION; SENESCENCE;
D O I
10.1016/j.anndiagpath.2013.11.004
中图分类号
R36 [病理学];
学科分类号
100103 [病原生物学];
摘要
Ovarian cancer is the fourth most common cause of cancer-related death in women. Bmi-1 is a stem cell factor implicated in many human malignancies with poor outcome. Few published reports on the expression of Bmi-1 in epithelial ovarian cancer were either experimental or performed on cell lines. This study evaluates the immunohistochemical expression of Bmi-1 protein in epithelial ovarian cancer tissue specimens and its relevance to the clinicopathologic prognostic variables and patient survival. Forty cases of epithelial ovarian cancer were selected according to the availability of paraffin-embedded tissue and the clinicopathologic and survival data. Immunohistochemistry was performed for anti-Bmi-1 antibody. Low and high Bmi-1 expression groups were compared with age, tumor stage, laterality, grade, histology, and patient survival. Bmi-1 expression was detected in 72.5% of cases, of which 42.5% had high expression. High Bmi-1 expression strongly associated with advanced International Federation of Gynecology and Obstetrics stages (P = .007), bilaterality (P = .01), and higher Gynecologic Oncology Group grades (P = .031) and carcinomas of serous histology (P = .027). It had no association with patient age. Bmi-1 expression displayed a significant inverse association with patient overall and mean survival (P = .006, P < .001). These observations suggested correlation between increased Bmi-1 expression and clinical progression in ovarian epithelial cancer. (c) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:58 / 62
页数:5
相关论文
共 41 条
[1]
Prognostic factors in ovarian cancer: how close are we to a complete picture? [J].
Agarwal, R ;
Kaye, SB .
ANNALS OF ONCOLOGY, 2005, 16 (01) :4-6
[2]
Beà S, 2001, CANCER RES, V61, P2409
[3]
Origins and molecular pathology of ovarian cancer [J].
Bell, DA .
MODERN PATHOLOGY, 2005, 18 :S19-S32
[4]
Berezovska OP, 2006, CELL CYCLE, V5, P1886
[5]
Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment [J].
Bertolini, Giulia ;
Roz, Luca ;
Perego, Paola ;
Tortoreto, Monica ;
Fontanella, Enrico ;
Gatti, Laura ;
Pratesi, Graziella ;
Fabbri, Alessandra ;
Andriani, Francesca ;
Tinelli, Stella ;
Roz, Elena ;
Caserini, Roberto ;
Lo Vullo, Salvatore ;
Camerini, Tiziana ;
Mariani, Luigi ;
Delia, Domenico ;
Calabro, Elisa ;
Pastorino, Ugo ;
Sozzi, Gabriella .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (38) :16281-16286
[6]
MiR-15a and MiR-16 Control Bmi-1 Expression in Ovarian Cancer [J].
Bhattacharya, Resham ;
Nicoloso, Milena ;
Arvizo, Rochelle ;
Wang, Enfeng ;
Cortez, Angelica ;
Rossi, Simona ;
Calin, George A. ;
Mukherjee, Priyabrata .
CANCER RESEARCH, 2009, 69 (23) :9090-9095
[7]
Expression of the p16INK4a gene product, methylation of the p16INK4a promoter region and expression of the polycomb-group gene BMI-1 in squamous cell lung carcinoma and premalignant endobronchial lesions [J].
Breuer, RHJ ;
Snijders, PJF ;
Sutedja, GT ;
Sewalt, RGAB ;
Otte, AP ;
Postmus, PE ;
Meijer, CJLM ;
Raaphorst, FM ;
Smit, EF .
LUNG CANCER, 2005, 48 (03) :299-306
[8]
Cancer of the ovary [J].
Cannistra, SA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (24) :2519-2529
[9]
BMI1 As a Novel Target for Drug Discovery in Cancer [J].
Cao, Liangxian ;
Bombard, Jenelle ;
Cintron, Katherine ;
Sheedy, Josephine ;
Weetall, Marla L. ;
Davis, Thomas W. .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2011, 112 (10) :2729-2741
[10]
BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer [J].
Crea, Francesco ;
Duhagon Serrat, Maria A. ;
Hurt, Elaine M. ;
Thomas, Suneetha B. ;
Danesi, Romano ;
Farrar, William L. .
INTERNATIONAL JOURNAL OF CANCER, 2011, 128 (08) :1946-1954